Becton, Dickinson and Company (NYSE: BDX) have been experiencing a series of noteworthy events. Major companies like SG Americas Securities LLC and Envestnet Portfolio Solutions Inc. have increased their holdings BDX, while others like BI Asset Management Fondsmaeglerselskab A/S and Quantbot Technologies LP trimmed theirs. The company issued a warning about delays to its blood culture product and also announced that it surpassed Scope 1 and 2 Reduction Milestones for FY 2023. When it comes to the market, the firm has been flagged as a strong value stock and experts set a new price target at $255.00. BDX recently experienced a drop in price, hitting a new 12-month low. Despite the company was criticised for its debt and stagnation, financial speculations propose that it could be undervalued by 36%. The firm also reported it surpassed Q2 earnings and revenue estimates. In a significant move, BDX announced its $4.2 billion acquisition of Edwards Lifesciences' critical care product group. Finally, the company got its name amongst Fortune's most innovative companies.
Becton Dickinson and BDX News Analytics from Mon, 16 Oct 2023 07:00:00 GMT to Sun, 14 Jul 2024 12:03:13 GMT -
Rating 4
- Innovation 6
- Information 6
- Rumor 5
